DARS1抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P09590(DARS1 Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

The DARS1 antibody targets the aspartyl-tRNA synthetase (DARS1), a key enzyme in protein synthesis that catalyzes the attachment of aspartic acid to its cognate tRNA during translation. As a member of the aminoacyl-tRNA synthetase (ARS) family, DARS1 is essential for maintaining translational fidelity and cellular homeostasis. Research on DARS1 has gained attention due to its link to neurological disorders, particularly hypomyelinating leukodystrophy (HLD), a rare genetic condition characterized by defective myelin formation in the central nervous system. Mutations in the *DARS1* gene disrupt enzyme function, leading to impaired protein synthesis in oligodendrocytes, which are critical for myelination.

DARS1 antibodies are primarily used in research to study the enzyme’s expression, localization, and functional alterations in disease models. They enable detection of DARS1 in tissues or cultured cells via techniques like Western blot, immunohistochemistry, or immunofluorescence. These tools help elucidate its role in cellular processes, including mitochondrial function and neurodevelopment. Commercially available DARS1 antibodies are typically raised in hosts like rabbits or mice, with validation in specific experimental systems.

Understanding DARS1’s pathophysiology through antibody-based studies holds promise for developing therapeutic strategies for HLD and related disorders, emphasizing the enzyme’s broader significance in both basic and clinical research.